EpiCept, Maxim Pharmaceuticals deal

EpiCept completed its previously announced acquisition of MAXM (see BioCentury, Sept. 12, 2005). EpiCept shareholders own about 72% of the combined company and MAXM stockholders own the remaining 28%....